Transdermal Diagnostics

Transdermal Diagnostics, founded in 2016 as a UK MedTech spin-out, is developing a disruptive, needle-free CGM system. Its patented platform utilizes reverse iontophoresis via hair follicles to sample interstitial fluid, coupled with an array of electrochemical sensors for calibration-free measurement. The company is pre-revenue and has secured non-dilutive grant funding and a pre-seed investment round to advance its first product towards clinical validation. Its mission is to transform chronic disease management, starting with diabetes, by improving user adherence and accessibility through a pain-free wearable.

Patented transdermal sensing platform using reverse iontophoresis to extract interstitial fluid through hair follicles. It combines a disposable adhesive patch with a miniaturized array of electrochemical sensors for needle-free, calibration-free biomarker extraction and quantification, connected to a reusable electronic controller and smartphone app.

Competes directly with major invasive CGM players like Dexcom, Abbott, and Medtronic. Also faces potential competition from other non-invasive glucose monitoring technologies in development (e.g., using optical sensors). Its key differentiator is the claimed combination of being truly needle-free, calibration-free, and using a novel transdermal extraction method.